Literature DB >> 10178667

Antidepressant selection and use and healthcare expenditures. An empirical approach.

W H Crown1, T R Hylan, L Meneades.   

Abstract

The purpose of this study was to evaluate whether 1-year total healthcare expenditures differed between patients who initiated therapy on a tricyclic antidepressant (TCA) or a selective serotonin reuptake inhibitor (SSRI) after controlling for initial antidepressant selection and antidepressant use pattern. A retrospective claims database covering a privately insured population in the US was used. Patients who initiated therapy in the outpatient setting (primary care or psychiatrist) were considered. Two-stage sample selection models were estimated that included controls for initial antidepressant selection and use pattern. The analyses indicated that: (i) self-selection due to initial antidepressant selection was a statistically significant determinant of expenditures for patients who initiated therapy on a TCA but not an SSRI; (ii) after controlling for initial antidepressant selection, antidepressant use pattern was a statistically significant and positive determinant of expenditures for both TCA and SSRI patients; and (iii) after controlling for initial antidepressant selection and use pattern, 1-year total direct healthcare expenditures were significantly lower for patients who initiated therapy on an SSRI than for patients who initiated therapy on a TCA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10178667     DOI: 10.2165/00019053-199813040-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  20 in total

1.  Cost-effectiveness of antidepressant treatment reassessed.

Authors:  S W Woods; J A Rizzo
Journal:  Br J Psychiatry       Date:  1997-03       Impact factor: 9.319

2.  Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.

Authors:  D A Sclar; L M Robison; T L Skaer; R S Galin; R F Legg; N L Nemec; T E Hughes; D P Buesching; M Morgan
Journal:  J Int Med Res       Date:  1995 Nov-Dec       Impact factor: 1.671

3.  Effect of antidepressant therapy on health care utilization and costs in primary care.

Authors:  T W Croghan; T J Lair; L Engelhart; W E Crown; C Copley-Merriman; C A Melfi; R L Obenchain; D P Buesching
Journal:  Psychiatr Serv       Date:  1997-11       Impact factor: 3.084

4.  Cost implications of initial antidepressant selection in primary care.

Authors:  G E Simon; P Fishman
Journal:  Pharmacoeconomics       Date:  1998-01       Impact factor: 4.981

5.  How can care for depression become more cost-effective?

Authors:  R Sturm; K B Wells
Journal:  JAMA       Date:  1995-01-04       Impact factor: 56.272

6.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

Authors:  F Song; N Freemantle; T A Sheldon; A House; P Watson; A Long; J Mason
Journal:  BMJ       Date:  1993-03-13

7.  Recognition, management, and outcomes of depression in primary care.

Authors:  G E Simon; M VonKorff
Journal:  Arch Fam Med       Date:  1995-02

8.  The deliberate misdiagnosis of major depression in primary care.

Authors:  K Rost; R Smith; D B Matthews; B Guise
Journal:  Arch Fam Med       Date:  1994-04

9.  Patterns of antidepressant use in community practice.

Authors:  G E Simon; M VonKorff; E H Wagner; W Barlow
Journal:  Gen Hosp Psychiatry       Date:  1993-11       Impact factor: 3.238

10.  Health care costs associated with depressive and anxiety disorders in primary care.

Authors:  G Simon; J Ormel; M VonKorff; W Barlow
Journal:  Am J Psychiatry       Date:  1995-03       Impact factor: 18.112

View more
  4 in total

1.  Current issues in the economics of depression management.

Authors:  D Thompson; E Richardson
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  There's a reason they call them dummy variables: a note on the use of structural equation techniques in comparative effectiveness research.

Authors:  William H Crown
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  The need for an iterative process for assessing economic outcomes associated with SSRIs.

Authors:  T L Skaer; D A Sclar; L M Robison; R S Galin
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

4.  Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.

Authors:  David Salkever; Eric Slade; Mustafa Karakus
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.